Liminatus Pharma (NASDAQ:LIMN – Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.03) earnings per share (EPS) for the quarter, FiscalAI reports.
Liminatus Pharma Trading Down 6.6%
Shares of Liminatus Pharma stock traded down $0.01 on Friday, hitting $0.14. The stock had a trading volume of 13,204,123 shares, compared to its average volume of 33,408,202. Liminatus Pharma has a 52-week low of $0.10 and a 52-week high of $4.33. The stock has a market cap of $7.09 million, a price-to-earnings ratio of -0.30 and a beta of 5.35. The company’s 50 day moving average price is $0.12 and its 200 day moving average price is $0.25.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Liminatus Pharma in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Liminatus Pharma has a consensus rating of “Sell”.
About Liminatus Pharma
Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.
Featured Stories
- Five stocks we like better than Liminatus Pharma
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
- Microsoft’s Maia 300 Chip Targets NVIDIA’s AI Dominance
- 3 Unexpected ETFs Crushing the Market This Summer
Receive News & Ratings for Liminatus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liminatus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
